Ind-Swift Laboratories Ltd vs Cipla Ltd
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Ind-Swift Laboratories Ltd currently has the stronger revenue growth signal.
Ind-Swift Laboratories Ltd and Cipla Ltd show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Ind-Swift Laboratories Ltd | Cipla Ltd |
|---|---|---|
| Current Price | ₹359.25 | ₹1,325.1 |
| Market Cap | ₹3,123.66 Cr. | ₹1.07 L Cr. |
| Industry | Pharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology |
| P/E Ratio | 48 | 29.9 |
| ROE (%) | 4.02 | 11.6 |
| Debt/Equity | 0.01 | 0.02 |
| Sales Growth 5Y (%) | -6.14 | 8.01 |
| Profit Growth 5Y (%) | 185.57 | 11.78 |
| Promoter Holding (%) | 42.93 | 29.22 |
| Revenue Rank | Rank 2 | Rank 3 |
| Margin Rank | Rank 3 | Rank 2 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | No information |